Title of Activity: Dear Diary…Unlocking The Secrets to Better Care of Patients with Atopic Dermatitis

Faculty:
Keisha Cash, DNP, APRN, DCNP, FNP-BC
Megan Lewis, MSN, RN, CPNP-PC
Karol Timmons, RN, MS, CPNP

Release Date: 10/12/2022
Expiration Date: 10/26/2022

Target Audience:
This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

CREDIT INFORMATION
Estimated time for completion: 105 minutes
THERE IS NO FEE FOR THIS ACTIVITY
This activity is awarded 1.75 Nursing Continuing Professional Development/Continuing Education (NCPD/CE) Credits.

To Receive Credit:
1. Attendance for entire education session
2. Complete/submit the evaluation.
3. Print out your certificate, as well as save it to your computer.

ACCREDITATION STATEMENT:
The Dermatology Nurses’ Association (DNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity is jointly provided by Dermatology Nurses’ Association and Excalibur Medical Education.

PROGRAM OVERVIEW
Program Purpose: The purpose of this activity is to provide healthcare providers current information on the management and treatment of atopic dermatitis. This activity provides healthcare providers a glimpse into how atopic dermatitis impacts quality of life, from the perspective of a variety of patients that live with the skin condition. The desired outcome would be that healthcare providers have improved knowledge and competency in managing and treating atopic dermatitis and improved ability to articulate care components necessary in effectively managing and treating patients with Atopic Dermatitis.

Learning Objectives
Upon successful completion of this educational program, the participant should be able to:

Assess the differences between mid, moderate, and severe AD, focusing specifically on how these differences affect disease management.
Discuss the key factors that drive the development of AD.
Discuss new emerging systemic and topical agents under investigation for the treatment of AD.
Discuss emerging research related to quality-of-life issues among patients with AD.

DISCLOSURE
It is the policy of DNA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by DNA prior to accreditation of the activity.

Planning committee members:
Linda Markham, BSN, RN, DNC, Executive Director & Program Director, Dermatology Nurses’ Association
Scott Kober, MBA, Managing Director, Excalibur Medical Education
Theresa Coyner, RN, MSN, ANP-BC, DCNP
Marianne Woody, FNP-BC, DCNP
Trudy Adamson, RN, MSN, DNC, AP-PD
have disclosed that they have no relevant financial relationships or conflicts of interest with ineligible companies related directly or indirectly to this educational activity.

Faculty:
Keischa Cash, DNP, APRN, DCNP, FNP-BC
Megan Lewis, MSN, RN, CPNP-PC
Karol Timmons, RN, MS, CPNP
have disclosed that they have no relevant financial relationships or conflicts of interest with ineligible companies related directly or indirectly to this educational activity.

All of the relevant financial relationships listed for these individuals have been mitigated.

COMMERCIAL SUPPORT
Support for this activity has been made possible through educational grants from Pfizer and Incyte.

Keischa Cash DNP, APRN, DCNP, FNP-BC

Nurse Practitioner, Academic Alliance in Dermatology

Appearances